Full Board vs Expedited vs Exempt: Why IRBs do That
It can seem perplexing or mysterious when an institutional review board (IRB) can review one study via expedited procedures, while a similar study may require full board review. And then some projects might be exempt from IRB review entirely.
Why do these different review pathways exist? And how do IRBs decide which path to take?
Join this webinar for an overview of the regulatory requirements governing these IRB review approaches. Advarra’s experts discuss what IRBs must consider, what might tip the scales for a study that could go either way, and what “expedited review” actually means.
Learning Objectives:
- Identify key regulatory requirements for IRB review of clinical research
- Describe how the different pathways can impact initial review, ongoing review, amendments, and other study activities
- Assess the likely review pathway for upcoming IRB submissions
Presented By
Jason Rush
BS, CIP
Senior Director, Regulatory
Advarra
Lauren Hartsmith
JD, CIP
Director, Regulatory Affairs
Advarra
Julie Ozier
MHL, CHRC, CIP
SVP of IRB Review and Institutional Official
Advarra
n/a
n/a
n/a
n/a
DATE: June 17, 2021
Time: 1 pm ET | 10 am PT
Duration: 1 hour